Biotechs targeting cancer, immunology likely to draw buyout bids

07/13/2011 | Reuters

Biotech companies that specialize in drugs for cancer, immune system diseases and brain conditions are likely to become attractive acquisition targets for Big Pharma, said investment bankers and other industry experts. Among such firms are Seattle Genetics, which has a drug candidate for two rare types of blood cancer, and Biogen Idec, which has multiple sclerosis drugs on the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA